Momenta Pharmaceuticals Appoints Georges Gemayel, Ph.D., to Board of Directors
September 21 2015 - 8:46PM
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced the appointment of Georges Gemayel,
Ph.D. to its Board of Directors effective January 1, 2016.
Dr. Gemayel has over 25 years of experience in the global
biopharmaceutical industry including management and executive
positions at biopharmaceutical companies such as Roche Labs,
Genzyme and Altus Pharmaceuticals.
“I am pleased to welcome Georges to Momenta’s
Board of Directors during this exciting stage in our Company’s
growth,” said Craig Wheeler, President and CEO, Momenta
Pharmaceuticals. “We believe his extensive experience in
biopharmaceutical product development and commercialization will
benefit the Company as we continue to advance our robust product
pipeline and work toward our goal of bringing multiple products to
market in the coming years.”
Dr. Gemayel has been a consultant for several
biotechnology companies and venture capital funds since 2010. Prior
to that he was President and CEO of Altus Pharmaceuticals from 2008
to 2009. From 2003 to 2008, he was Executive Vice President at
Genzyme Corporation where he was responsible for the company's
worldwide therapeutics businesses. From 1988 to 2003, he held
progressively senior roles at Hoffmann La-Roche and Roche Labs. Dr.
Gemayel currently serves on the Board of Directors of the
publically listed companies Raptor Pharmaceutical Corp. and
Supernus Pharmaceuticals and of Dimension Therapeutics, a privately
owned company. He is Chairman of the Board of Directors of
privately owned biotechnology companies Orphazyme, OxThera, and
Enterome Bioscience. He previously served on the Board of
Directors of NPS Pharmaceuticals, Prosensa, Adolor Corporation,
FoldRx, Epitherapeutics and Altus Pharmaceuticals.
Dr. Gemayel completed his doctorate in pharmacy
at St. Joseph University in Beirut, Lebanon, and earned a Ph.D. in
pharmacology at Paris-Sud University in Paris, France.
About Momenta
Momenta Pharmaceuticals is a biotechnology
company specializing in the detailed structural analysis of complex
drugs and is headquartered in Cambridge, MA. Momenta is
applying its technology to the development of generic versions of
complex drugs, biosimilar and potentially interchangeable
biologics, and to the discovery and development of novel
therapeutics for oncology and autoimmune indications.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does
not form a part of this press release.
Our logo, trademarks, and service marks are the
property of Momenta Pharmaceuticals, Inc. All other trade names,
trademarks, or service marks are property of their respective
owners.
Forward Looking Statements
Statements in this press release regarding
management's future expectations, beliefs, intentions, goals,
strategies, plans or prospects, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including but not limited to statements about Dr. Gemayel
benefitting the Company; advancing our product pipeline; and
bringing multiple products to market in the coming years.
Forward-looking statements may be identified by words such as
"anticipate," "believe," "continue," "could," "hope," "target,"
"project," "goal," "objective," "guidance," "plan," "potential,"
"predict," "might," "estimate," "expect," "intend," "may," "seek",
"should," "will," "would," "look forward" and other similar words
or expressions, or the negative of these words or similar words or
expressions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors, including those
referred to under the section "Risk Factors" in the Company's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2015,
filed with the Securities and Exchange Commission, as well as other
documents that may be filed by the Company from time to time with
the Securities and Exchange Commission. As a result of such risks,
uncertainties and factors, the Company's actual results may differ
materially from any future results, performance or achievements
discussed in or implied by the forward-looking statements contained
herein. The Company is providing the information in this press
release as of this date and assumes no obligations to update the
information included in this press release or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
INVESTOR CONTACT:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
MEDIA CONTACT:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
Momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024